Clinical Evaluation of Feprazone on Rheumatoid Arthritis by the Group:Comparison Method through a Double-Blind Controlled Study in Multiple Hospitals

概要

論文の詳細を見る
The efficacy, safety, and usefulness of feprazone on classical and definite rheumatoid arthritis according to ARA diagnostic criteria, were examined by the group comparison method through a double-blind controlled study in multiple hospitals, dosing feprazone (300 mg/day) and phenylbutazone (300 mg/day) as a reference standard for six weeks. (1) Feprazone was found to be equally or more effective than phenylbutazone on rheumatoid arthritis. (2) As for safety, it was statistically significant that edema was occurred in feprazone less than phenylbutazone and.gastro-intestinal tolerance was also seemed to be better than it. Feprazone (28.1%) was lower than phenylbutazone (38.1%) in side effects however, no statistically significant difference was found. The detail investigation revealed no serious side effect caused by feprazone. (3) Feprazone (68.5%) was higher than phenylbutazone (54.2%) in usefulness, however, no statistically significant difference was found. Consequently, feprazone was assessed to be equally or more effective on rheumatoid arthritis and safer to use than phenylbutazone.
一般社団法人日本臨床薬理学会の論文